All Trials

An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable/metastatic HER2-positive biliary tract cancer (gallbladder or cholangiocarcinoma; ECOG 0–1) receiving first-line cisplatin/gemcitabine ± durvalumab or pembrolizumab are randomized to add zanidatamab versus standard therapy alone, with primary efficacy evaluated in IHC 3+ tumors. Zanidatamab is a bispecific, bi-epitopic anti-HER2 antibody designed to enhance receptor clustering/internalization and immune-mediated cytotoxicity.

ClinicalTrials.gov ID: NCT06282575

A Phase 1 Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors (dose-escalation monotherapy) or treatment‑naïve, CLDN18.2‑positive gastric/GEJ/esophageal adenocarcinoma (combination cohorts) receive givastomig (TJ033721/ABL111), a CLDN18.2 × 4‑1BB bispecific antibody that conditionally activates 4‑1BB on T cells, either alone or with nivolumab plus chemotherapy. Key requirements include ECOG 0–1, known PD‑L1 CPS, CLDN18.2 positivity for expansion/combination, and no prior CLDN18.2 therapy or prior PD‑1/PD‑L1 therapy in the combination setting.

ClinicalTrials.gov ID: NCT04900818

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable/metastatic, HER2‑negative, microsatellite‑stable gastric/GEJ/esophageal adenocarcinoma with PD‑L1 CPS ≥1 after exactly one prior PD‑1/PD‑L1–chemotherapy regimen are randomized to paclitaxel plus ramucirumab with or without nivolumab. Nivolumab is a PD‑1–blocking antibody; ramucirumab is a VEGFR2 antagonist, and paclitaxel is a microtubule stabilizer.

ClinicalTrials.gov ID: NCT06203600

A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: First-line trial in adults with unresectable/metastatic, centrally confirmed HER2-positive gastric/GEJ adenocarcinoma (main cohort PD-L1 CPS ≥1; exploratory CPS <1) comparing trastuzumab deruxtecan (HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor) plus a fluoropyrimidine ± pembrolizumab versus standard trastuzumab plus platinum/fluoropyrimidine chemotherapy ± pembrolizumab. Key exclusions include prior HER2 therapy, significant cardiac/pulmonary disease, and history of ILD/pneumonitis.

ClinicalTrials.gov ID: NCT06731478

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with relapsed/refractory CD19-positive B‑cell malignancies (DLBCL/high‑grade B‑cell lymphoma, transformed/Richter, B‑ALL/B‑LBL, or CML in lymphoid blast crisis) receive targeted conditioning with 131‑I apamistamab (anti‑CD45 radiolabeled mAb delivering marrow/lymphoid radiation) followed by 19‑28z CD19‑directed CAR T cells. Prior CD19 therapies (including CAR T) are allowed with confirmed CD19 expression; key exclusions include uncontrolled infection, significant cardiac disease, active GVHD/autoimmune disease requiring systemic T‑cell suppression, and inadequate organ function.

ClinicalTrials.gov ID: NCT04512716

Adaptive Radiation for Abdominopelvic Metastases (ARAM)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic solid tumors limited to abdominopelvic lesions (ECOG 0–1, no prior RT to target, ≤5 active metastases) receive adaptive stereotactic body radiation therapy with daily online plan adaptation, using dose-escalated SBRT (8–10 Gy/fx) to optimize target coverage while monitoring for grade ≥3 toxicity. Single-arm dose-escalation study; excludes peritoneal carcinomatosis and active extra-abdominopelvic disease.

ClinicalTrials.gov ID: NCT05880667

Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with symptomatic malignant gastric outlet obstruction from distal gastric or duodenal tumors, suitable for surgical bypass and general anesthesia, are randomized to laparoscopic Roux-en-Y gastric bypass versus standard loop gastrojejunostomy for palliative restoration of oral intake. The trial compares postoperative gastric emptying and diet tolerance, along with complications, reoperation, short-term survival, and quality of life.

ClinicalTrials.gov ID: NCT05986890

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic gastric/GEJ adenocarcinoma that is HER2-negative, CLDN18.2-positive, and PD-L1–positive (ECOG 0–1) are randomized to pembrolizumab plus CAPOX or mFOLFOX6 with either zolbetuximab or placebo. Zolbetuximab is a CLDN18.2-targeted IgG1 monoclonal antibody that mediates ADCC/CDC; key exclusions include prior metastatic-line therapy (beyond one initial dose), active autoimmune disease, immune pneumonitis, CNS mets, significant GI obstruction/bleeding, and >grade 1 neuropathy.

ClinicalTrials.gov ID: NCT06901531

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Newly diagnosed, unresectable/metastatic, SSTR-positive, well-differentiated G1–G2 (Ki-67 &lt;10%) advanced GEP-NETs with high disease burden (adolescents/adults, ECOG 0–1) randomized to [177Lu]Lu-DOTA-TATE plus octreotide LAR versus octreotide LAR alone. [177Lu]Lu-DOTA-TATE is a somatostatin receptor–targeted peptide receptor radionuclide therapy delivering beta-emitting 177Lu via DOTA-TATE to SSTR2-expressing tumors.

ClinicalTrials.gov ID: NCT06784752

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with locally advanced/metastatic solid tumors—emphasizing urothelial carcinoma—harboring actionable FGFR3 alterations receive the selective FGFR3 inhibitor LOXO-435 (LY3866288) as monotherapy or combined with pembrolizumab ± enfortumab vedotin. Cohorts include FGFR inhibitor–naïve, post–FGFR inhibitor, and first-line mUC settings; key exclusions include uncontrolled CNS disease and significant ocular/cardiac risks.

ClinicalTrials.gov ID: NCT05614739